Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
PDXHCI002 Etoposide
3.1623
Topo II
Chemotherapy
 -0.0891 -0.05192
PDXHCI002 Etoposide
10.0
Topo II
Chemotherapy
 -0.1795 0.04694
PDXHCI002 Dasatinib
0.001
BCR/ABL
MAPK/nRTK
 1.0381 0.00410
PDXHCI002 Dasatinib
0.0031623
BCR/ABL
MAPK/nRTK
 0.9986 0.00800
PDXHCI002 Dasatinib
0.01
BCR/ABL
MAPK/nRTK
 0.8868 0.00267
PDXHCI002 Dasatinib
0.031623
BCR/ABL
MAPK/nRTK
 0.6912 0.00797
PDXHCI002 Dasatinib
0.1
BCR/ABL
MAPK/nRTK
 0.6068 -0.00670
PDXHCI002 Dasatinib
0.31623
BCR/ABL
MAPK/nRTK
 0.5700 -0.00968
PDXHCI002 Dasatinib
1.0
BCR/ABL
MAPK/nRTK
 0.4943 0.00074
PDXHCI002 Dasatinib
3.1623
BCR/ABL
MAPK/nRTK
 0.2113 0.01470
PDXHCI002 Dasatinib
10.0
BCR/ABL
MAPK/nRTK
 0.0322 0.03630
PDXHCI002 Trametinib
0.0001
MEK
MAPK/nRTK
 1.0139 0.01244
PDXHCI002 Trametinib
0.00031623
MEK
MAPK/nRTK
 1.0294 -0.00407
PDXHCI002 Trametinib
0.001
MEK
MAPK/nRTK
 0.9542 -0.00557
PDXHCI002 Trametinib
0.0031623
MEK
MAPK/nRTK
 0.8534 -0.00267
PDXHCI002 Trametinib
0.01
MEK
MAPK/nRTK
 0.7665 -0.00134
PDXHCI002 Trametinib
0.031623
MEK
MAPK/nRTK
 0.6785 -0.00322
PDXHCI002 Trametinib
0.1
MEK
MAPK/nRTK
 0.6492 0.01268
PDXHCI002 Trametinib
0.31623
MEK
MAPK/nRTK
 0.6425 0.01352
PDXHCI002 Trametinib
1.0
MEK
MAPK/nRTK
 0.6467 0.01550
PDXHCI002 Saracatinib
0.001
SRC
MAPK/nRTK
 1.0019 0.00529
PDXHCI002 Saracatinib
0.0031623
SRC
MAPK/nRTK
 0.9420 0.00665
PDXHCI002 Saracatinib
0.01
SRC
MAPK/nRTK
 0.8218 0.00393
PDXHCI002 Saracatinib
0.031623
SRC
MAPK/nRTK
 0.5749 0.01681
PDXHCI002 Saracatinib
0.1
SRC
MAPK/nRTK
 0.4588 0.01271